Konsume
Interval Day Week Month
Range 30 Day 90 Day 6 Months 1 Yr
Newswire Search Past 90 Days 11 stories 4 Publishers
Trending Today
Sort By: Snapshot
Buzz
Media Coverage
World View
Related Topics
Topic # Mentions Topic Reach
summit6-
positive5-
summit therapeutics4-
therapeutics4-
akeso3-
survival3-
nsclc3-
Prominent Journalists
Byline Articles Written Avg Reach
RTTNews Staff Writer 4 -
By Salong Debbarma 2 -
by PR Newswire 2 -
Gayathry Prakash 1 -
Prabha Kurup 1 -
Meghana Keshavan 1 -


Lunit And Summit Collaborate On AI-Powered Biomarker Discovery For Ivonescimab
Gayathry Prakash — rttnews.com


Summit Therapeutics Stock Rises 7% Over Initiation Of Global Phase II Study Of Ivonescimab
RTTNews Staff Writer — rttnews.com


AstraZeneca invests $2 billion in Summit Therapeutics
Meghana Keshavan — statnews.com


AstraZeneca to invest $2bn in Summit for ADC combination therapies
By Salong Debbarma — pharmaceutical-business-review.com


Summit Therapeutics (SMMT): Time To Take A Look Ahead Of The FDA Decision
Prabha Kurup — rttnews.com


Akeso Reports Positive Overall Survival Results For Ivonescimab In First-Line PD-L1-Positive NSCLC
RTTNews Staff Writer — rttnews.com


Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
by PR Newswire — thailand-business-news.com


Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
by PR Newswire — thailand-business-news.com


Summit Therapeutics Stock Rises 8%
RTTNews Staff Writer — rttnews.com


Akeso secures China NMPA authorisation for ivonescimab combo
By Salong Debbarma — pharmaceutical-business-review.com

Execution: 3.38 Seconds. 33.81 mb used.